Genetic Signatures

Genetic Signatures Gross Margin

The Gross Margin of Genetic Signatures (GSS.AX) as of Oct 28, 2026 is -88.02 %. In the previous year, Gross Margin was 48.95 % — a change of -279.82% (lower).

Gross Margin

-88.02 %

YoY

-279.82%

Last updated:

Gross Margin of Genetic Signatures is 2026 -88.02 % . Gross Margin of Genetic Signatures was 2025 48.95 % . It decreases by -279.82% lower compared to the previous year.

For Genetic Signatures, the gross margin of -88.0% is down versus 20.4% a few years ago.

The Genetic Signatures Gross Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Margin
Date
Gross Margin
Jan 1, 2019
59.27 AUD
Jan 1, 2020
-21.00 AUD
Jan 1, 2021
15.10 AUD
Jan 1, 2022
20.36 AUD
Jan 1, 2023
-75.21 AUD
Jan 1, 2024
44.11 AUD
Jan 1, 2025
48.95 AUD
Jan 1, 2026
-88.02 AUD
The Genetic Signatures Gross Margin history
YEARGross MarginYoY
-88.02 %-279.82%
48.95 %+10.97%
44.11 %-158.66%
-75.21 %-469.36%
20.36 %+34.87%
15.10 %-171.90%
-21.00 %-135.43%
59.27 %-1.70%
60.29 %+4.74%
57.56 %-16.44%
68.89 %+10.88%
62.12 %+17.08%
53.06 %-9,769.74%
-0.55 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genetic Signatures Stock analysis

What does Genetic Signatures do? Genetic Signatures Ltd. develops real-time PCR based products for infectious disease detection, focusing on the 3base platform technology. The company commercializes its MDx 3base platform, enabling high-volume hospitals and pathology labs to screen for infectious pathogens with high specificity and rapid results. Products under the EasyScreen brand include the EasyScreen Pan-Enteric Detection Kit, EasyScreen STI Genital Pathogen Detection, and EasyScreen Viral Meningitis Detection Kit, sold into diagnostic and research marketplaces. The firm targets hospitals and pathology laboratories as key buyers of its diagnostic solutions. Its products are designed for routine detection of infectious diseases, with the EasyScreen suite addressing specific pathogen categories like enteric, STI, and viral meningitis. The company focuses on research and commercialization of genetic signature identification for disease detection, leveraging its 3base platform for high-throughput screening. Genetic Signatures Ltd. generates revenue through the sale of its real-time PCR based products under the EasyScreen brand. The MDx 3base platform technology is central to its commercial strategy, providing a solution for rapid, specific pathogen screening in clinical settings. The company's product portfolio includes multiple kits targeting different infectious disease categories, all sold into the diagnostic and research markets. Genetic Signatures is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genetic Signatures stock

Gross Margin of Genetic Signatures is -88.02 % in 2026.

Gross Margin of Genetic Signatures changed from 48.95 % to -88.02 %, representing a -279.82% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Gross Margin Genetic Signatures since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's Genetic Signatures with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Genetic Signatures

All Key Metrics — Genetic Signatures